Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
81 results about "Inositol monophosphate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Inositol Monophosphate: Inositol monophosphate is a form of inositol that is used in supplements. Inositol is a substance produced by the human body and is involved with fat and cell metabolism.
Composition for gelatin coating, gelatin coating, and preparation using the same
Owner:WAKUNAGA PHARMA CO LTD
Vitamin feed additive premix for sea fish
InactiveCN103039724AImprove the body's immunityNo adverse effects on palatabilityAnimal feeding stuffPhosphateVitamin B6 synthesis
The invention relates to a vitamin feed additive premix for sea fish, and belongs to the technical field of feed additives for fish culture. The vitamin feed additive premix is prepared by uniformly mixing vitamin A, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B 12, nicotinic acid, folic acid, calcium pantothenate, biotin, inositol, VC (vitamin C) phosphate ester and zeolite powder according to a certain percentage ratio and further adding into feed according to the proportion of 0.5%-1%. The vitamin feed additive premix disclosed by the invention has the following advantages: (1) the vitamin feed additive premix can be used during the whole culture cycle; (2) the adding amount in the feed for the sea fish is 0.5%-1%; (3) the immunity of fresh water fish can be effectively enhanced and the survival rate is improved; (4) the vitamin feed additive premix disclosed by the invention has no adverse effects on palatability of the feed; and (5) raw material sources used by the vitamin feed additive premix disclosed by the invention are stable, the price is low, and the production process is simple.
Owner:青岛玛斯特生物技术有限公司
Inositol-Phosphate Derivatives and Method of Detecting Inositol-1-Phosphate
The present invention relates to inositol phosphate derivatives, in which the inositol phosphate is substituted with one or two reactive groups G or one or two conjugated substances or molecules M, said reactive group(s) G or said substance(s) or molecule(s) M being linked to IP1 via a linkage group L, M being chosen from the following group: a tracer, an immunogen, a member of a binding partner pair, a solid support.Application: tools allowing the study of the inositol phosphate cycle and therefore, indirectly, the study of seven transmembrane domain receptors coupled to phospholipase C, receptors having a tyrosine kinase activity, and in general enzymes involved in the variations of the intracellular concentration of IP1.
Owner:CIS BIO INT
Potentially fluorogenic compounds
InactiveUS6416970B1Avoid disadvantagesMicrobiological testing/measurementGroup 5/15 element organic compoundsPhosphateStaphylococcus species
The invention provides compounds of formula (I) in which R1, R2, R3, R4 and R5 are independently selected from hydrogen and chromogenic substituents, and X is selected from the group consisting of hydroxyl; OR6 wherein R6 is selected from the group consisting of C1-C4 alkyl; and O-Me+ wherein Me+ is a cation derived from an organic or inorganic base. A preferred species of formula (I) is 4-Methylumbelliferyl myo-inositol-1-phosphate and salts thereof with an organic or inorganic base. The invention also provides fluorogenic methods for detecting various pathogenic bacteria, e.g., Listeria, Staphylococcus and Clostridium species, using substrates containing at least one formula (I) compound. A kit for detecting a phosphatidyl-inositol-specific phospholipase C enzyme as an indication of bacterial activity is disclosed.
Owner:BIOSYNTH
Method for preparing inositol through enzymic catalysis and inositol
InactiveCN105925643AImprove conversion efficiencySimple production processFermentationGlucose polymersD-Glucose
The invention relates to a method for preparing inositol through enzymic catalysis. The method comprises the following steps: performing enzyme-catalyzed conversion on a polysaccharide or an oligosaccharide which takes glucose as a unit to obtain glucose-1-phosphate; performing enzyme-catalyzed conversion on the glucose-1-phosphate to obtain glucose-6-phosphate; performing enzyme-catalyzed conversion on the glucose-6-phosphate to obtain inositol-1-phosphate; performing enzyme-catalyzed conversion on the inositol-1-phosphate to obtain inositol. The invention also provides an inositol product which is prepared according to the method. According to the method, the conversion efficiency of the inositol is effectively improved; moreover, a production process is simple, pollution-free, and low in production cost.
Owner:浙江欣诺医药有限公司
A road paving material using ceramic waste and construction waste and its preparation method
ActiveCN104072066BSolve pollutionAvoid secondary pollutionSolid waste managementFiberPortland cement
Owner:湖南钰鹏环保科技有限公司
Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
ActiveUS20210253600A1Improved efficacy profileImproved safety profilePharmaceutical delivery mechanismGroup 3/13 element organic compoundsNeuro-degenerative diseasePhospholipid
Owner:HIBERCELL INC
Chromenopyrimidine derivatives as phosphatidylinsitol phosphate kinase inhibitors
ActiveUS20200392162A1Improved efficacy profileImproved safety profileOrganic chemistryAntineoplastic agentsDepressantNeuro-degenerative disease
Owner:HIBERCELL INC
Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors
InactiveUS20200392156A1Improved efficacy profileImproved safety profileOrganic chemistryAntineoplastic agentsNeuro-degenerative diseasePhospholipid
Owner:HIBERCELL INC
Inositol-3-phosphate synthase mutant and application of inositol-3-phosphate synthase mutant in construction of corynebacterium glutamicum with high yield of glutamine
ActiveCN113201524AEnhanced ability to produce glutamineIncrease productionBacteriaMicroorganism based processesBacterosiraOrganic chemistry
The invention relates to the field of bioengineering, in particular to an inositol-3-phosphate synthase mutant and application of the inositol-3-phosphate synthase mutant in construction of corynebacterium glutamicum for high yield of glutamine. It is found that after 84th-site serine of inositol-3-phosphate synthase is mutated into other amino acids, the glutamine production capacity of corynebacterium glutamicum can be enhanced in corynebacterium glutamicum. Compared with a wild strain without mutation, the corynebacterium glutamicum has the advantages that the glutamine production capacity of the corynebacterium glutamicum is enhanced, the glutamine yield is increased to 30.7 g / L from 28.5 g / L, the acid production is increased by 7.7%, and screening and construction of a glutamine high-yield strain are facilitated.
Owner:MEIHUA BIOTECH LANGFANG CO LTD
Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
PendingUS20200331913A1Improved efficacy profileImproved safety profileGroup 3/13 element organic compoundsImmunological disordersNeuro-degenerative diseasePhospholipid
Owner:HIBERCELL INC
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
ActiveUS20210317136A1Improve efficacyImprove securityGroup 3/13 element organic compoundsImmunological disordersNeuro-degenerative diseasePhospholipid
Owner:HIBERCELL INC
Method for enzymatically preparing highly concentrated myo-inositol
The present disclosure relates to a method for preparing myo-inositol using myo-inositol monophosphate synthase consisting of an amino acid sequence of SEQ ID NO: 1 and / or myo-inositol monophosphate phosphatase consisting of an amino acid sequence of SEQ ID NO: 3.
Owner:CJ CHEILJEDANG CORP
Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
ActiveUS20140080893A1Induced deathReduces and prevents tumor cell growthOrganic active ingredientsCompound screeningKinase activityPhosphatidylinositol 5-phosphate
The invention features methods for identifying compounds that modulate the activity of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) Inhibitors of PI5P4K can be used in, for example, the treatment or prevention of cell proliferation dis orders (e.g., the prevention of tumor cell growth in p53 mutated cancers).
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Preparation method of high-purity sugammadex sodium
ActiveCN111978435AReduce the risk of oxidationSuppress generationOrganic active ingredientsMuscular disorderInositol pentaphosphateSugammadex Sodium
The invention discloses a preparation method of high-purity sugammadex sodium. The high-purity sugammadex sodium is prepared from inositol phosphate and derivatives thereof. The specific process comprises the following steps of adding a specific type of protective agent into a crude sugammadex sodium product, and performing recrystallizing under the protection of inert gas to obtain a pure sugammadex sodium product, wherein the protective agent is selected from the inositol phosphate and the derivatives thereof, such as inositol hexaphosphate and salts or esters thereof, partial degradation products of the inositol hexaphosphate, such as inositol pentaphosphate, inositol tetraphosphate, inositol triphosphate, inositol diphosphate and inositol monophosphate, and one or a mixture of two or more of the above-mentioned substances and salts or esters thereof in any proportion. The method is simple and convenient to operate, high in product purity, good in safety, few in anaphylactic reaction, good in economical efficiency and more suitable for industrial production.
Owner:HEFEI BOSIKC PHARMTECH CO LTD
Lithium diagnosis/measuring reagent kit and lithium concentration determination method
InactiveCN101464311AFast measurementImprove accuracyMicrobiological testing/measurementColor/spectral properties measurementsEnzymatic ColorimetryAbsorbance
The invention relates to a kit for diagnosing / measuring lithium by utilizing the technologies of the enzymic colorimetry and the enzyme linked immunosorbent assay, wherein, the activity of the kit can be inhibited by lithium. The invention further relates to a method, a principle and the composition and the components of a reagent for measuring the concentration of lithium, and belongs to the technical field of medical / industrial / environmental inspection and measurement. The main components of the kit include a buffer solution, reduced coenzyme, magnesium chloride, inositol-1-phosphate, an oxaloacetic acid, a pyruvic acid, inositol-1-phosphatase, phosphoenolpyruvate carboxykinase, malic dehydrogenase and a stabilizer. Through mixing a check sample and a lithium sample respectively with the reagent by a certain volume ratio, a series of enzymatic reactions occur, then the reactant is placed under an ultraviolet / visible light analyzer, the degree / velocity of the decrease in absorbance at 340 nm of the dominant wavelength is detected, and the difference in the degree / velocity of the decrease between the check sample and lithium sample is compared, thereby measuring the concentration of lithium.
Owner:SUZHOU ANJ BIOTECHNOLOGY CO LTD
Cellular production of glucaric acid through recombinant expression of uronate dehydrogenase and myo-inositol oxygenase
ActiveUS8835147B2Improve throughputA large amountAnimal cellsBacteriaMyo-Inositol-1-Phosphate SynthaseGlucaric Acid
Owner:MASSACHUSETTS INST OF TECH
Method for producing inositol by complete phosphorolysis of cellulose
ActiveCN110857443AComplete phosphorylation achievedImprove conversion rateFermentationCellulosePhosphorylation
The invention relates to the field of enzymatic catalytic preparation of inositol, in particular to an enzymatic preparation method for producing inositol by complete phosphorolysis of cellulose. According to the preparation method of inositol, pretreated cellulose (the main component is fiber polysaccharide) is used as a substrate for the enzyme catalytic reaction; and cellulose polysaccharide phosphorylase, cellobiose phosphorylase, polyphosphate glucokinase, phosphoglucomutase, inositol-1-phosphate synthase and inositol monophosphatase are adopted to catalyze complete phosphorolysis of cellulose polysaccharide into inositol. By optimizing the multienzyme reaction process and controlling the reaction temperature in stages, the conversion efficiency of the substrate and the inositol yieldare significantly improved, and the reaction time is shortened. The technical method realizes the complete phosphorolysis of the cellulose substrate, and can also be used for other in-vitro multi-enzyme reaction systems to catalyze cellulose polysaccharide for production of hydrogen, electricity or other bio-based chemicals.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Application of effective inhibitor of III-type phosphatidylinositol phosphate kinase in preparing drug for treating or preventing influenza virus infection
ActiveCN109453174ABroad-spectrum anti-influenza virus activityOrganic active ingredientsAntiviralsFuranSide effect
The invention discloses application of effective inhibitor of III-type phosphatidylinositol phosphate kinase in preparing drug for treating or preventing influenza virus infection. Research results prove that the effective inhibitor, namely a small molecule compound: 6-amino-N-[3-[4-(4-morpholinyl)pyridine[3', 2':4, 5] furan [3, 2-d] pyrimidine-2-base] phenyl]3-pyridine carboxamide can inhibit copying of influenza A virus subtype H1N1 amantadine drug-tolerant strain, influenza A virus subtype H6N6 strain, influenza A virus subtype H7N8 strain and influenza B virus in a dosage-dependent mannerwithin a nontoxic range, thereby having great wide-spectrum influenza virus resistant activity. Therefore, the small molecular compound is safe, efficient and little in toxic and side effect during clinical treatment of influenza.
Owner:浙江安维珞诊断技术有限公司
Dunaliellaviridis myo-Inositol-1-phosphatesynthase gene, and protein coded thereby and application thereof
The invention relates to a dunaliellaviridis myo-Inositol-1-phosphatesynthase gene (DvMIPS), and a protein coded thereby and application thereof. The gene is a DNA (Deoxyribonucleic Acid) sequence shown as SEQ ID NO1. According to the invention, the myo-Inositol-1-phosphatesynthase gene DvMIPS is separated from dunaliellaviridis for the first time; and conversion of yeast cells shows that the gene not only has the phosphatesynthase function, but also has the application value of improving the biological salt tolerance character.
Owner:SHANGHAI UNIV
Engineering bacterium for producing inositol as well as construction method and application of engineering bacterium
The invention provides an engineering bacterium for producing inositol. The engineering bacterium comprises a host bacterium and a plasmid vector transferred into the host bacterium; a gene for encoding inositol-1-phosphate synthase is introduced into the plasmid vector, or a gene for encoding inositol-1-phosphate synthase and a gene for overexpressing and encoding inositol monophosphase are introduced into the plasmid vector at the same time. The invention also provides a construction method and application of the engineering bacterium for producing inositol. According to the engineering bacterium, endogenous enzyme is overexpressed while the exogenous enzyme is utilized, gene regulation and control are conducted in combination with RED recombination, the yield of inositol and the yield of a carbon source are increased step by step, and therefore rapid growth of a host and efficient production of inositol are achieved with sucrose, glucose, glycerol and other simple carbon sources as sources and through mutual coordination of production and growth.
Owner:BEIJING UNIV OF CHEM TECH
Ascorbic acid production from D-glucose in yeast
Herein is disclosed a method of generating ascorbic acid from yeast transformed with a mannose epimerase. In a further embodiment, the yeast can be further transformed with a myoinositol phosphatase. In the method, the transformed yeast can produce L-ascorbic acid from D-glucose. The transformed yeast has been observed to have increased growth rate, cell density, or survival when cultured on appropriate media.
Owner:TATE & LYLE INGREDIENTS AMERICAS INC
SHIP-Deficiency to Increase Megakaryocyte Progenitor Production
InactiveUS20100260730A1Increases in megakaryocyte progenitorsIncrease the number ofBiocideSugar derivativesProgenitorIn vivo
Owner:UNIV OF SOUTH FLORIDA
Lithium diagnosis/measuring reagent kit and lithium concentration determination method
InactiveCN101464325AFast measurementImprove accuracyMicrobiological testing/measurementColor/spectral properties measurementsSucrose phosphorylasePhosphoric acid
The invention relates to a kit for diagnosing / measuring lithium by utilizing the technologies of the enzymic colorimetry and the enzyme linked immunosorbent assay, wherein, the activity of the kit can be inhibited by lithium. The invention further relates to a method, a principle and the composition and the components of a reagent for measuring the concentration of lithium, and belongs to the technical field of medical / industrial / environmental inspection and measurement. The main components of the kit include a buffer solution, coenzyme, magnesium chloride, inositol-1-phosphate, sucrose, inositol-1-phosphatase, sucrose phosphorylase, fructose dehydrogenase and a stabilizer. Through mixing a check sample and a lithium sample respectively with the reagent by a certain volume ratio, a series of enzymatic reactions occur, then the reactant is placed under an ultraviolet / visible light analyzer, the degree / velocity of the increase in absorbance at 340 nm of the dominant wavelength is detected, and the difference in the degree / velocity of the increase between the check sample and lithium sample is compared, thereby measuring the concentration of lithium.
Owner:SUZHOU ANJ BIOTECHNOLOGY CO LTD
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascula calcification
PendingUS20220339171A1Organic active ingredientsPharmaceutical delivery mechanismDosing regimenRegimen
The present invention relates to compounds, pharmaceutical compositions, combined preparations, and dosage regimens for treating, inhibiting the progression, and preventing cardiovascular calcification, and in particular, coronary calcification, aortic artery calcification, and aortic valve calcification comprising inositol phosphates. In a particular aspect the disclosure provides a dosage regimen for treating, inhibiting the progression, or preventing cardiovascular calcification comprising the administration of about 200 mg to about 700 mg of myo-inositol hexaphosphate per administration.
Owner:SANIFIT THERAPEUTICS SA
IP and IP analogs dosage regimens for the treatment of ectopic calcifications
The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and / or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg / kg to 9 mg / kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.
Owner:SANIFIT THERAPEUTICS SA
Assay for inositol phosphorylceramide synthase activity
Owner:AUREOGEN BIOSCIENCES INC
Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
ActiveUS9493813B2Induced deathReduces and prevents tumor cell growthOrganic active ingredientsCompound screeningKinase activityPhosphatidylinositol 5-phosphate
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Method For Testing A Compound For A Therapeutic Effect And A Diagnostic Method
A method for testing compound for a therapeutic effect utilizing a non-human animal or cell having disruption in the prostatic acid phosphatase gene resulting in a decrease or absence in the activity or the level of prostatic acid phosphatase. The compound may be used for treating disorders related to unbalanced phosphatidylinositol phosphate cascade or signaling pathway. Diagnostic methods and methods for treating the disorders with therapeutic compounds or by gene therapy are also disclosed.
Owner:CHEMPATH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com